SYNTERA BIORISK
SpeciesSheep, cattle & goatsReleaseFrance · 2026-09-07
  1. Global Overview
  2. Europe
  3. France
  4. Bluetongue
Country–disease dossierFrance · Bluetongue
View economic evidence Run scenarioCompare interventionsInspect BCR assumptions Vaccine & intervention marketTrade analysis
France cross-disease portfolio FRANCE DISEASE PROFILE · LINKED WORKSPACE

Bluetongue

Official evidence, 18-region exposure and transparent national planning economics.

Profile readyEvidence + editable CBA
African swine feverofficially freeHighly pathogenic avian influenzacurrent outbreak low national risk levelBluetongueenzootic active btv3Bovine tuberculosisofficially free with residual outbreaksFoot-and-mouth diseaseofficially freePeste des petits ruminantsofficially freeNewcastle diseaseno current event in registered sourceClassical swine feverofficially freeSheep pox and goat poxofficially freeLumpy skin diseaseno active outbreak vaccination controls continueBovine viral diarrhoeaendemic control programmeJohne's diseaseendemic control framework current prevalence unavailableEpizootic haemorrhagic diseaseno current season outbreak after recent epidemic
Official disease status · 2026-09-04

Bluetongue

BTV-3, BTV-4 and BTV-8 are enzootic in metropolitan France including Corsica; 800 BTV-3 outbreaks were reported from 1 June to 3 September 2026.

Selected geography
France
Susceptible livestock
24.06m
Evidence nature
Observed / official
Exposure layer

France · susceptible livestock

IGN COG 2026
Exposure is livestock inventory—not inferred prevalence. Regional selection updates supported evidence; the CBA remains explicitly national because regional cost evidence is unavailable.
Validated exposure

France

cattle16.21m
sheep6.46m
goats1.39m

Agreste SAA 2025 provisional observations; source grain retained.

Official signal at selected grain
  • BTV-3 outbreaks since 1 June 2026800 outbreaks
  • BTV-8 outbreaks since 1 June 20260 outbreaks
  • BTV-4 outbreaks in Corsica during 20260 outbreaks
Observed economics · national/source scope
Observed direct loss · national
N/A
Published programme cost · source scope
nearly EUR22m State-funded vaccine purchase
Monetised trade effect
N/A

No compatible current France-specific direct-loss estimate is registered; no value is inferred.

Relevant wildlife & interface

Wildlife evidence

No compatible current national wildlife-population layer is registered.

Population denominators remain unavailable unless explicitly registered; qualitative host evidence is not converted into a count.
ILLUSTRATIVE

Illustrative scenario—country-specific intervention evidence unavailable.

The planning parameters are retained, but the BCR is not estimated in this public profile.

Open Impact CalculatorWhy these assumptions?
Control choices

Default option scenarios

  1. 01Voluntary vaccinationPlanning option retained for explicit activation in Scenario Lab
  2. 02Vector-season surveillancePlanning option retained for explicit activation in Scenario Lab
  3. 03Movement certification and disinsectionPlanning option retained for explicit activation in Scenario Lab
Trade & movement

Documented consequence

National movement is unrestricted for enzootic serotypes; EU and third-country movements can require vaccination, testing and/or disinsection.

The registered official source documents controls but not a compatible France-wide monetised consequence.
Release principle: every France disease has a complete decision workspace. Missing observed economics stay visible as N/A; modelled planning values are separately labelled, editable and never presented as evidence.
Sustainability & One HealthCountry-specific GHG, AMU/AMR and biodiversity results remain withheld until compatible evidence is registered; none is inferred from the disease profile.
Request complete Decision Brief